Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 11/20 | 0.62 |
| ▸ | CASP7 | P55210 | 7/20 | 0.57 |
| ▸ | CASP1 | P29466 | 5/20 | 0.57 |
| ▸ | CASP9 | P55211 | 4/20 | 0.57 |
| ▸ | MME | P08473 | 1/20 | 0.56 |
| ▸ | ECE1 | P42892 | 1/20 | 0.56 |
| ▸ | CASP4 | P49662 | 3/20 | 0.54 |
| ▸ | CASP10 | Q92851 | 3/20 | 0.53 |
| ▸ | CASP8 | Q14790 | 2/20 | 0.53 |
| ▸ | ELANE | P08246 | 1/20 | 0.52 |
| ▸ | REN | P00797 | 1/20 | 0.51 |
| ▸ | CTSK | P43235 | 3/20 | 0.51 |
| ▸ | CTSB | P07858 | 2/20 | 0.51 |
| ▸ | CASP5 | P51878 | 1/20 | 0.51 |
| ▸ | CASP6 | P55212 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3140616 | 1.00 | CASP3 (0.62) | CASP3CASP7CASP1CASP9MME | |
| SCHEMBL7112627 | 0.96 | CASP3 (0.58) | CASP3CASP7CASP1CASP9MME | |
| SCHEMBL3692638 | 0.96 | CASP3 (0.58) | CASP3CASP7CASP1CASP9MME | |
| SCHEMBL7383742 | 0.95 | CASP3 (0.67) | CASP3CASP7CASP1CASP9MME | |
| SCHEMBL4420464 | 0.95 | CASP3 (0.67) | CASP3CASP7CASP1CASP9MME | |
| SCHEMBL3692630 | 0.94 | CASP3 (0.56) | CASP3CASP7CASP1CASP9MME | |
| SCHEMBL18740358 | 0.92 | CASP3 (0.58) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL29453232 | 0.92 | MME (0.58) | CASP3CASP1MMEECE1CTSK | |
| SCHEMBL30579903 | 0.91 | REN (0.59) | CASP3CASP7CASP1CASP9CASP8 | |
| SCHEMBL7155003 | 0.91 | MME (0.59) | CASP3CASP1MMEECE1CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 473 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025033948-A1 | NON-VIRAL DUAL PLASMID VECTOR CAPABLE OF HIGHLY EFFICIENT GENE EXPRESSION, STEM CELL EXPRESSING SAME, AND DIFFERENTIATED HEMATOPOIETIC SYSTEM CELL | 마루테라퓨틱스 주식회사 | 2025-02-13 | — | — | WO | claimed |
| CN-118416072-A | Application of secatinib in relieving and treating diseases related to programmed necrosis | 福建医科大学 | 2024-08-02 | — | — | CN | claimed |
| CN-117653717-A | Application of cholesterol hydroxylase CH25H in preparation of medicine for promoting degradation of hepatitis B virus Core protein | 吉林大学第一医院 | 2024-03-08 | — | — | CN | claimed |
| CN-110545837-B | Use of pathways associated with autoinducers for inducing apoptosis and anti-infective therapy | 清华大学 | 2022-09-27 | — | — | CN | claimed |
| US-20170248604-A1 | METHODS FOR DIAGNOSIS, PROGNOSIS AND METHODS OF TREATMENT | NODALITY INC (US) | 2017-08-31 | — | — | US | claimed |
| US-7411000-B2 | Process of inhibiting cell death in injured cartilage | THE SCRIPPS RESEARCH INSTITUTE (US) | 2008-08-12 | — | — | US | claimed |
| US-20050276809-A1 | comprising antibodies that specifically bind caspase-8 as inhibitors; cancer; activation of the receptor-interacting protein (RIP, a serine-threonine kinase) and Jun N-terminal kinase induce cell death with the morphology of autophagy | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-12-15 | — | — | US | claimed |
| US-20020183258-A1 | Process of inhibiting cell death in injured cartilage | THE SCRIPPS RESEARCH INSTITUTE | 2002-12-05 | — | — | US | claimed |
| EP-4105216-B1 | DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | GENFLEET THERAPEUTICS SHANGHAI INC (CN) | 2026-05-20 | — | — | EP | disclosed |
| US-20260130924-A1 | COMPOSITIONS AND METHODS OF TREATING SUBJECTS WITH BRCA1 MUTATION OR DEFICIENCY | UNIV TEXAS (US) | 2026-05-14 | — | — | US | disclosed |
| US-12612413-B2 | Heteroaryl compounds as inhibitors of programmed necrosis pathway, composition and method using the same | ACCRO BIOSCIENCE (HK) LIMITED (CN) | 2026-04-28 | — | — | US | disclosed |
| EP-4716691-A2 | ONCOLYTIC PEPTIDES | The Johns Hopkins University (US) | 2026-04-01 | — | — | EP | disclosed |
| US-12590126-B2 | Compounds for selective disruption of protein-protein interactions | SYNTHEX, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| EP-4709765-A1 | IMMUNOTHERAPEUTIC PROTEINS | Macfarlane Burnet Institute for Medical Research and Public Health Limited (AU) | 2026-03-18 | — | — | EP | disclosed |
| US-20020052323-A1 | Quinoline-(C=O)-(multiple amino acids)-leaving group compounds for pharmaceutical compositions and reagents | MP BIOMEDICALS, LLC | 2002-05-02 | — | — | US | disclosed |
| WO-2002018341-A2 | QUINOLINE- (C=O) - (DI-, TRI- AND TETRAPEPTIDE) DERIVATIVES AS CASPASE INHIBITORS | ENZYME SYSTEMS PRODUCTS, INC. (US) | 2002-03-07 | — | — | WO | disclosed |
| WO-2001079495-A1 | METHOD OF INDUCING TUMOR CELL APOPTOSIS USING TRAIL/APO-2 LIGAND GENE TRANSFER | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2001-10-25 | — | — | WO | disclosed |
| WO-2001074376-A2 | CATHEPSIN INHIBITORS IN CANCER TREATMENT | PARKER HUGHES INSTITUTE (US) | 2001-10-11 | — | — | WO | disclosed |
| WO-1998036057-A9 | THYMOCYTE CASPASE ACTIVITY AND NEGATIVE SELECTION | — | 1999-01-07 | — | — | WO | disclosed |
| WO-1998036057-A1 | THYMOCYTE CASPASE ACTIVITY AND NEGATIVE SELECTION | DANA FARBER CANCER INSTITUTE (US) | 1998-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612413-B2 | Heteroaryl compounds as inhibitors of programmed necrosis pathway, composition and method using the same | CASP6, CASP3, BAX | CASP3 2/4885CASP7 10/4885CASP1 6/4885 |
| US-12590126-B2 | Compounds for selective disruption of protein-protein interactions | DDB1, DAXX, DDIT3 | CASP3 2048/4885CASP7 2031/4885CASP1 1911/4885 |
| US-20260130924-A1 | COMPOSITIONS AND METHODS OF TREATING SUBJECTS WITH BRCA1 MUTATION OR DEFICIENCY | BRCA1, GPX4, GPX1 | CASP3 83/4885CASP7 227/4885CASP1 136/4885 |
| US-20020052323-A1 | Quinoline-(C=O)-(multiple amino acids)-leaving group compounds for pharmaceutical compositions and reagents | CASP3, CASP1, BAX | CASP3 1/4885CASP7 5/4885CASP1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.